LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

92.2 -6.17

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

90.83

Максимум

93.01

Ключови измерители
By Trading Economics
Приходи	-6.3M -53M
Продажби	2.8M 51M
EPS	-0.82
Марж на печалбата	-103.131
Служители	283
EBITDA	-7.6M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+53.38% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.1B 6.4B
Предишно отваряне	98.37
Предишно затваряне	92.2

Настроения в новините

By Acuity

46%

54%

125 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.02.2026 г., 23:53 ч. UTC

Горещи акции

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27.02.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

28.02.2026 г., 21:36 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28.02.2026 г., 15:20 ч. UTC

Печалби

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28.02.2026 г., 14:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28.02.2026 г., 14:38 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28.02.2026 г., 13:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28.02.2026 г., 13:44 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28.02.2026 г., 13:14 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28.02.2026 г., 02:32 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28.02.2026 г., 02:00 ч. UTC

Придобивния, сливания и поглъщания

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28.02.2026 г., 02:00 ч. UTC

Придобивния, сливания и поглъщания

Six Months, 9 Offers and $81 Billion. How -2-

28.02.2026 г., 00:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27.02.2026 г., 23:46 ч. UTC

Придобивния, сливания и поглъщания

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27.02.2026 г., 23:33 ч. UTC

Придобивния, сливания и поглъщания

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

27.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

27.02.2026 г., 21:30 ч. UTC

Печалби

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27.02.2026 г., 21:30 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27.02.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27.02.2026 г., 21:17 ч. UTC

Печалби

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27.02.2026 г., 21:10 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27.02.2026 г., 21:09 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27.02.2026 г., 21:00 ч. UTC

Печалби

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27.02.2026 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27.02.2026 г., 20:24 ч. UTC

Пазарно говорене

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27.02.2026 г., 20:23 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27.02.2026 г., 20:12 ч. UTC

Пазарно говорене

Nike Seen With Further Challenges in China -- Market Talk

27.02.2026 г., 19:44 ч. UTC

Пазарно говорене

Gold Caps Historic Month -- Market Talk

27.02.2026 г., 19:39 ч. UTC

Печалби

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

53.38% нагоре

12-месечна прогноза

Среден 142.23 USD 53.38%

Висок 176 USD

Нисък 125 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

125 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.